Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech
company that leverages advancements in science and technology to
build breakthrough companies that transform human wellness, today
reported its financial results for the three months ended May 31,
2024 (“Q2 2024”) compared to the same period last year (“Q2 2023”).
All financial figures are in Canadian dollars unless otherwise
indicated.
Second Quarter Highlights
- Net revenue from
continued operations of $3.9 million in Q2 2024 compared to $7.7
million in Q2 2023.
-
Gross profit before inventory adjustment of $1.9 million in Q2
2024, representing gross margin of 49%, compared to $3.7 million,
or 48% gross margin, in Q2 2023.
-
Operating costs and professional fees decreased to $2.9 million in
Q2 2024 compared to $3.9 million in Q2 2023.
-
Adjusted EBITDA loss was $0.9 million in Q2 2024 compared to $0.2
million in Q2 2023.
- Cash and cash equivalents increased
to $2.1 million at the end of Q2 2024 versus $1.5 million at the
end of 2023.
“Our performance in the second quarter of 2024
is another clear indication that we must move on from operating our
legacy cannabis business segments and find other solutions that
have exposure to the broader wellness market” said Meni Morim, CEO
of Lifeist. “We are working to finalize the sale of CannMart and
shift our focus and resources to advancing Mikra Cellular Sciences.
We are actively rebuilding our marketing and sales strategies from
the ground up to increase sales, improve margins, and transform
Lifeist into a profitable leading nutraceutical company offering
superior health and wellness products backed by science.”
Financial Summary
Net revenue was $3.9 million in Q2 2024 compared
to $7.7 million in Q2 2023.
Gross profit before inventory adjustment was
$1.9 million in Q2 2024 versus $3.7 million in the same period last
year, with margins of 49% in Q2 2024 compared to 48% in Q2
2023.
Total expenses decreased $1.4 million to $3.0 million in Q2 2024
compared to $4.4 million in the previous year. The decrease
reflects the Company’s efforts to control costs and enhance
efficiencies as evidenced by improvements across multiple cost
categories including salaries ($455,000 decrease), office and
general expenses ($72,000 decrease), professional fees ($200,000
decrease), sales and marketing ($234,000 decrease), and share-based
compensation ($380,000 decrease)
Adjusted EBITDA, a non-IFRS measure, was a loss
of $0.9 million in Q2 2024 compared to $0.2 million in Q2 2023 and
net loss from continuing operations was $1.4 million, or ($0.047)
per diluted share, in Q2 2024 compared to a loss of $2.2 million,
or ($0.015) per diluted share, in Q2 2023. The change in both
adjusted EBITDA loss and net loss was largely the result of the
restructuring of CannMart Labs in Q2 2024, costs which are
non-recurring.
Balance Sheet and Cash Flow
Cash and cash equivalents were $2.1 million on
May 31, 2024, compared to $1.5 million on November 30, 2023.
Inventories were $2.3 million on May 31, 2024
compared to $4.5 million on November 30, 2023.
The working capital position was negative $2.6
million on May 31, 2024.
Net cash used in operations was $0.4 million in
Q2 2024 compared to net cash used in operations of $0.6 million in
Q2 2023.
Additional Information
The Company’s complete financial statements and
management’s discussion & analysis (“MD&A”) for the three
and six months ended May 31, 2024 are available on Lifeist’s
website (www.lifeist.com) and SEDAR+ (www.sedarplus.ca).
About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic
wellness revolution, Lifeist leverages advancements in science and
technology to build breakthrough companies that transform human
wellness. Portfolio business units include Mikra, a biosciences and
consumer wellness company developing and selling innovative
products for cellular health, and CannMart, which operates a B2B
wholesale distribution business facilitating recreational cannabis
sales to Canadian provincial government control boards including
for CannMart Labs, a BHO extraction facility producing high margin
cannabis 2.0 products.
Information on Lifeist and its businesses can be
accessed through the links below:
www.lifeist.com https://wearemikra.com/
https://cannmart.com
Contact: Meni MorimCEOLifeist
Wellness Inc.Ph: 647-362-0390 Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press release.
Non-IFRS Financial Measures
Management evaluates the Company’s performance
using a variety of measures, including “Net loss before income tax,
depreciation and amortization” and “Adjusted EBITDA”. The non-IFRS
measures discussed below should not be considered as an alternative
to or to be more meaningful than revenue or net loss. These
measures do not have a standardized meaning prescribed by IFRS and
therefore they may not be comparable to similarly titled measures
presented by other publicly traded companies and should not be
construed as an alternative to other financial measures determined
in accordance with IFRS.
The Company believes these non-IFRS financial
measures provide useful information to both management and
investors in measuring the financial performance and financial
condition of the Company.
Management uses these and other non-IFRS
financial measures to exclude the impact of certain expenses and
income that must be recognized under IFRS when analyzing
consolidated underlying operating performance, as the excluded
items are not necessarily reflective of the Company’s underlying
operating performance and make comparisons of underlying financial
performance between periods difficult. From time to time, the
Company may exclude additional items if it believes doing so would
result in a more effective analysis of underlying operating
performance. The exclusion of certain items does not imply that
they are non-recurring.
- Current and
deferred income taxes, depreciation and amortization, and
share-based compensation were excluded from the Adjusted EBITDA
calculation as they do not represent cash expenditures.
- Other income
consisting of gain on disposal of subsidiary, interest income,
realized gain on disposition of AFS investments, unrealized gain on
derivatives and other miscellaneous non-recurring income were
excluded from Adjusted EBITDA calculation.
- Non-recurring
costs related to restructuring and legacy issues were excluded from
Adjusted EBITDA calculation.
- Impairment loss
relating to goodwill, customer list, domains and brand names were
excluded from Adjusted EBITDA calculation.
- Impairment loss
relating to receivable is a provision for expected credit loss to
an associate and was excluded from Adjusted EBITDA
calculation.
- Share of
associates loss, net of tax, is excluded due to lack of
control.
Forward Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not historical in nature
contain forward-looking information. Forward-looking information
can be identified by words or phrases such as “may”, “expect”,
“likely”, “should”, “would”, “plan”, “anticipate”, “intend”,
“potential”, “proposed”, “estimate”, “believe” or the negative of
these terms, or other similar words, expressions and grammatical
variations thereof, or statements that certain events or conditions
“may” or “will” happen.
The forward-looking information contained
herein, including, without limitation, statements related to: the
Company taking steps to address operational structural issues and
to act on future opportunities to increase revenue and achieve
profitability, and its expectations from such actions to increase
revenue growth and achieve profitability are made as of the date of
this press release and is based on assumptions management believed
to be reasonable at the time such statements were made, including,
without limitation, Lifeist’s ability to implement beneficial
structural changes to its operations in the short term including,
including additional cost cutting measures, the Company’s ability
to quickly respond to future opportunities to increase revenue, as
well as other considerations that are believed to be appropriate in
the circumstances. While we consider these assumptions to be
reasonable based on information currently available to management,
there is no assurance that such expectations will prove to be
correct. By its nature, forward-looking information is subject to
inherent risks and uncertainties that may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. A
variety of factors, including known and unknown risks, many of
which are beyond our control, could cause actual results to differ
materially from the forward-looking information in this press
release. Such factors include, without limitation: the failure of
the Company to implement meaningful structural operational changes,
its inability to develop its business as anticipated and to
increase revenues and/or its profitable margin on such revenues,
unanticipated changes to current regulations that would adversely
impact the Company’s businesses, increased regulatory costs
relating to the Company’s cannabis business, competition from
others, risks related to any slowdown in the expected demand for
cannabis and nutraceutical products in general and those of
CannMart and Mikra in particular, regulatory risk, risks relating
to the Company’s ability to execute its business strategy and the
benefits realizable therefrom and risks specifically related to the
Company’s operations. Additional risk factors can also be found in
the Company’s current MD&A which has been filed under the
Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned
not to put undue reliance on forward-looking information. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable law. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.
Source: Lifeist Wellness Inc.
Lifeist Wellness (TSXV:LFST)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Lifeist Wellness (TSXV:LFST)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024